1. Scrip

BIO-Europe Spring 2019: Nanoform Harnesses Physics To Enhance Drug Candidate Viability

 
• By Mike Ward

Nanoform’s chief commercial officer Christian Jones outlines how the company uses physics to enhance drug discovery and development for its pharma partners.

Video interview
Nanoform's Christian Jones speaks to Scrip

Helsinki-based Nanoform is looking to use nanotechnology and drug particle engineering to address challenges of solubility, permeability and bioavailability for candidates that companies in the industry is already developing in the clinic, as well as offering a better chance for discovery molecules to move into clinical development. Christian Jones, chief commercial officer, explained the company’s technological approach and its business strategy.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.